Pediatrix Medical Group, Inc. Files Definitive Proxy Statement

Ticker: MD · Form: DEF 14A · Filed: Mar 28, 2024 · CIK: 893949

Pediatrix Medical Group, INC. DEF 14A Filing Summary
FieldDetail
CompanyPediatrix Medical Group, INC. (MD)
Form TypeDEF 14A
Filed DateMar 28, 2024
Risk Level
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Executive Compensation, Pediatrix Medical Group, Corporate Governance

TL;DR

<b>Pediatrix Medical Group, Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023, detailing executive compensation and corporate governance matters.</b>

AI Summary

Pediatrix Medical Group, Inc. (MD) filed a Proxy Statement (DEF 14A) with the SEC on March 28, 2024. Pediatrix Medical Group, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 28, 2024. The filing covers the fiscal year ending December 31, 2023. The company was formerly known as MEDNAX, INC. and PEDIATRIX MEDICAL GROUP INC. The filing includes details on executive compensation and equity awards. The company's principal executive offices are located at 1301 Concord Terrace, Sunrise, FL 33323.

Why It Matters

For investors and stakeholders tracking Pediatrix Medical Group, Inc., this filing contains several important signals. This DEF 14A filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions on proposals presented at the annual meeting. The document provides transparency into the company's financial performance and how it relates to executive pay, which can impact investor confidence and stock valuation.

Risk Assessment

Risk Level: — Pediatrix Medical Group, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement, indicating no immediate significant financial or operational risks are being disclosed beyond standard business operations.

Analyst Insight

Review the executive compensation details and any shareholder proposals to inform voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did Pediatrix Medical Group, Inc. file this DEF 14A?

Pediatrix Medical Group, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 28, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Pediatrix Medical Group, Inc. (MD).

Where can I read the original DEF 14A filing from Pediatrix Medical Group, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Pediatrix Medical Group, Inc..

What are the key takeaways from Pediatrix Medical Group, Inc.'s DEF 14A?

Pediatrix Medical Group, Inc. filed this DEF 14A on March 28, 2024. Key takeaways: Pediatrix Medical Group, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 28, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company was formerly known as MEDNAX, INC. and PEDIATRIX MEDICAL GROUP INC..

Is Pediatrix Medical Group, Inc. a risky investment based on this filing?

Based on this DEF 14A, Pediatrix Medical Group, Inc. presents a moderate-risk profile. The filing is a routine proxy statement, indicating no immediate significant financial or operational risks are being disclosed beyond standard business operations.

What should investors do after reading Pediatrix Medical Group, Inc.'s DEF 14A?

Review the executive compensation details and any shareholder proposals to inform voting decisions. The overall sentiment from this filing is neutral.

How does Pediatrix Medical Group, Inc. compare to its industry peers?

Pediatrix Medical Group operates within the healthcare services sector, specifically focusing on physician services.

Are there regulatory concerns for Pediatrix Medical Group, Inc.?

The filing is a standard DEF 14A, subject to SEC regulations for public companies regarding disclosure of corporate actions and executive compensation.

Industry Context

Pediatrix Medical Group operates within the healthcare services sector, specifically focusing on physician services.

Regulatory Implications

The filing is a standard DEF 14A, subject to SEC regulations for public companies regarding disclosure of corporate actions and executive compensation.

What Investors Should Do

  1. Review the detailed executive compensation breakdown for key executives.
  2. Analyze any shareholder proposals and the board's recommendations.
  3. Note the company's former names and historical context provided in the filing.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for annual meetings and executive compensation, not a comparison to a prior period's financial performance.

Filing Stats: 4,675 words · 19 min read · ~16 pages · Grade level 12.4 · Accepted 2024-03-28 06:50:52

Filing Documents

Executive Compensation: Compensation Discussion and Analysis ("CD&A")

Executive Compensation: Compensation Discussion and Analysis ("CD&A") 29 Section I: A Message to Our Shareholders 29 Section II: Compensation and Talent Committee Report 30 2024 Proxy Statement i Pediatrix Medical Group, Inc. TABLE OF CONTENTS Section III: Executive Summary 31 2023 Business Highlights 31 2023 Financial Information 32 Response to Say-on-Pay Vote and Shareholder Outreach 32 CEO Pay At-A-Glance 36 Elements of Pay 37 Section IV: Overview of the Executive Compensation Program 38 The Guiding Principles of Our Pay Philosophy 38 How Pay Decisions Are Made 38 Section V: The Executive Compensation Program in Detail 40 Base Salary 40 2023 Base Salary Decisions 40 Annual Bonuses 40 2023 Annual Bonus Program 40 Equity-Based Awards 43 2023 Equity-Based Awards 43 Actual Performance and Shares Earned under the 2023 Performance Share Awards 47 Other Practices, Policies & Guidelines 47 Equity Grant Practices 47 Clawback Policy 47 Stock Ownership and Retention Policy 48 Anti-Hedging and Anti-Pledging Policy 49 Retirement and Deferred Compensation Plans 49 Benefits and Perquisites 49 Employment Agreements 49 Summary Compensation Table 51 Grants of Plan-Based Awards in 2023 52 Outstanding Equity Awards at 2023 Fiscal Year-End 53 Stock Vested in Fiscal Year 2023 54 Potential Payments Upon Termination or Change in Control 54 Chief Executive Officer Pay Ratio 57 Pay Versus Performance 58 Director Compensation 64 Share Ownership Information 65

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 65 Independent Auditors 67 Independent Auditors 67 Fees Paid to Independent Auditors 67 Audit Fees 67 Audit-Related Fees 67 Tax Fees 67 All Other Fees 67 Pre-Approval Policies and Procedures 67 Proposal 2: Ratification of the Appointment of Independent Auditors 68 Proposal 3: Advisory Vote on Executive Compensation 69 Other Business 71 Availability of Annual Report on Form 10-K 71 Information Concerning Shareholder Proposals 71 Pediatrix Medical Group, Inc. ii 2024 Proxy Statement TABLE OF CONTENTS This proxy statement includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this proxy statement are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise, except as required by law. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially fro

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing